virusin the notyet peer reviewed study of 60 healthy adults the vaccine induced virusneutralizing antibodies in those given two doses a result inline with a previous earlystage us trial the burst of announcements followed publication last week of results of moderna incs vaccine trial showing similarly promising early results modernas vaccine also uses a messenger rna platformits encouraging that all these vaccines seem to induce antibodies in people said former world health organization who assistant directorgeneral mariepaule kieny of the french research institute inserm this proves that the science is moving forward very quickly which is a good signcoronavirus complete coverage long way to gonone of these leading contenders has shown side effects that could sideline their efforts so far but all must still prove they are safe and effective in trials involving thousands of subjects including those at highrisk for severe covid19 such as the elderly and people with diabeteshistorically just 6 of vaccine candidates end up making it to market often after a yearslong testing process vaccine makers hope to dramatically compress that timeline through faster trials and by manufacturing at scale even before the products prove successfulseveral manufacturers have us government backing with a goal of having a coronavirus vaccine by years end as cases continue to rise at a record pacethe oxfordastrazeneca vaccine is one of 150 in development globally but is considered the most advanced latestage trials have begun in brazil and south africa and are due to start in the united states where the infection prevalence is highestin its phase i trial the vaccine induced socalled neutralizing antibodies the kind that stop the virus from infecting cells in 91 of individuals a month after they got one dose and in 100 of subjects who got a second dose these levels were on par with the antibodies produced by people who survived covid19 a key benchmark of potential successoxford researcher sarah gilbert said the trial could not determine whether one or two doses would be needed to provide immunitythe vaccine known as azd1222 also induced the body to make t cells activating a second part of the immune system that experts increasingly believe will be important for a lasting immune responserecent studies show that some recovered patients who tested negative for coronavirus antibodies developed t cells in response to their infection scientists think both are important aspects of an effective coronavirus vaccine dr mike ryan head of whos emergencies program said the generation of both tcell and neutralizing antibody responses was positive adding there is a long way to go watch covid19 promising results in early studies raise vaccine hopes